ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

INNL Innocoll Holdings - Ordinary Shares (MM)

2.35
0.00 (0.00%)
Apr 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 2.00
Ask Price 2.45
News -
Company Name Stock Ticker Symbol Market Type
Innocoll Holdings - Ordinary Shares (MM) INNL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 2.35 20:00:00
Open Price Low Price High Price Close Price Prev Close
2.35 2.35
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.35 USD

Innocoll Holdings - Ordinary Shares (MM) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 929.18M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Innocoll AG News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No INNL Message Board. Create One! See More Posts on INNL Message Board See More Message Board Posts

Historical INNL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year0.000.000.000.0000.000.00%
3 Years0.000.000.000.0000.000.00%
5 Years0.000.000.000.0000.000.00%

Innocoll AG Description

Innocoll AG was incorporated in Delaware under the name Innocoll, Inc. in December 1997 and renamed Innocoll Holdings, Inc., in May 2004. In July 2013, Innocoll Holdings, Inc., was re-domiciled from the United States to Germany pursuant to a contribution-in-kind and share for share exchange into the recently formed Innocoll GmbH, a German limited liability company, as a result of which Innocoll Holdings, Inc. became Innocoll GmbH's wholly-owned subsidiary. The Company is a commercial stage specialty pharmaceutical company, with late stage development programs targeting areas of significant unmet medical need. The Company's product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. XaraColl, is an implantable, bioresorbable collagen sponge designed to provide sustained post-operative pain relief through controlled delivery of bupivacaine at the surgical site.

Your Recent History

Delayed Upgrade Clock